- Home
- ACCS vs CLGN Comparison
ACCS vs CLGN Comparison
Compare ACCS & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACCS
- CLGN
- Stock Information
- Founded
- ACCS 1988
- CLGN 2004
- Country
- ACCS United States
- CLGN Israel
- Employees
- ACCS N/A
- CLGN N/A
- Industry
- ACCS Publishing
- CLGN Industrial Specialties
- Sector
- ACCS Consumer Discretionary
- CLGN Health Care
- Exchange
- ACCS Nasdaq
- CLGN Nasdaq
- Market Cap
- ACCS 34.4M
- CLGN 33.8M
- IPO Year
- ACCS N/A
- CLGN N/A
- Fundamental
- Price
- ACCS $8.50
- CLGN $2.04
- Analyst Decision
- ACCS Strong Buy
- CLGN Strong Buy
- Analyst Count
- ACCS 1
- CLGN 2
- Target Price
- ACCS $14.00
- CLGN $11.50
- AVG Volume (30 Days)
- ACCS 14.7K
- CLGN 24.2K
- Earning Date
- ACCS 11-11-2025
- CLGN 12-01-2025
- Dividend Yield
- ACCS N/A
- CLGN N/A
- EPS Growth
- ACCS N/A
- CLGN N/A
- EPS
- ACCS N/A
- CLGN N/A
- Revenue
- ACCS $21,332,000.00
- CLGN $2,402,000.00
- Revenue This Year
- ACCS $0.03
- CLGN $1,617.28
- Revenue Next Year
- ACCS $7.32
- CLGN $83.54
- P/E Ratio
- ACCS N/A
- CLGN N/A
- Revenue Growth
- ACCS 23.82
- CLGN 248.62
- 52 Week Low
- ACCS $7.79
- CLGN $1.31
- 52 Week High
- ACCS $13.35
- CLGN $4.98
- Technical
- Relative Strength Index (RSI)
- ACCS 32.58
- CLGN 44.76
- Support Level
- ACCS $8.89
- CLGN $1.85
- Resistance Level
- ACCS $9.72
- CLGN $2.27
- Average True Range (ATR)
- ACCS 0.58
- CLGN 0.11
- MACD
- ACCS -0.02
- CLGN -0.01
- Stochastic Oscillator
- ACCS 4.05
- CLGN 54.35
About ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.